Strategic Partnerships Target collaborations with large biopharma and contract research organizations that need scalable, validated diagnostics for oncology, leveraging Veracyte's expanding test menu and MRD capabilities to strengthen joint development and companion diagnostic opportunities.

Clinical Expansion Capitalize on recent launch news such as breast cancer chemo-sparing tests and Prosigna LDT in the US to push into hospitals and cancer centers exploring precision medicine, offering diagnostic care pathways that reduce unnecessary interventions and accelerate treatment decisions.

Enterprise Growth Position Veracyte as a growth partner for health systems seeking cost containment and improved outcomes by promoting tests that minimize invasive procedures, supported by strong revenue trajectory and a robust funding base to scale deployment.

Technology Enablement Highlight the company’s end-to-end product development capabilities including software and bioinformatics as differentiators for turnkey diagnostic solutions, inviting collaborations on data integration, real-world evidence, and AI-powered decision support.

Key Executives Engage with leadership changes such as the new chief development and technology officer to align sales pitches with future product roadmaps, emphasizing ongoing innovation across diagnostic assays, software, and product program management.